NEWSAR
Multi-perspective news intelligence
SRCThe Guardian - World News
LANGEN
LEANCenter-Left
WORDS375
ENT10
THU · 2026-04-02 · 21:33 GMTBRIEF NSR-2026-0402-49932
News/Trump threatens 100% tariff on US drug makers that don’t str…
NSR-2026-0402-49932News Report·EN·Economic Impact

Trump threatens 100% tariff on US drug makers that don’t strike deals to lower prices

Donald Trump is threatening 100% tariffs on US drug manufacturers who don't agree to lower domestic drug prices. The tariffs, targeting branded drugs and their active ingredients, aim to align US prices with those in other high-income countries.

Lauren Aratani and ReutersThe Guardian - World NewsFiled 2026-04-02 · 21:33 GMTLean · Center-LeftRead · 2 min
Trump threatens 100% tariff on US drug makers that don’t strike deals to lower prices
The Guardian - World NewsFIG 01
Reading time
2min
Word count
375words
Sources cited
2cited
Entities identified
10entities
Quality score
100%
§ 01

Briefing Summary

AI-generated
NEWSAR · AI

Donald Trump is threatening 100% tariffs on US drug manufacturers who don't agree to lower domestic drug prices. The tariffs, targeting branded drugs and their active ingredients, aim to align US prices with those in other high-income countries. Exemptions are available for generic, orphan, veterinary, and specialty drugs, as well as companies that strike pricing deals with the White House and onshore production. Larger companies have 120 days to negotiate deals to avoid or reduce the tariff, while smaller companies have 180 days. The move comes amid pressure to lower consumer prices and Trump's broader economic agenda to address the rising cost of living, which he blames on the Biden administration. Some industry groups are concerned the policy favors large drugmakers.

Confidence 0.90Sources 2Claims 5Entities 10
§ 02

Article analysis

Model · rule-based
Framing
Economic Impact
Political Strategy
Tone
Measured
AI-assessed
CalmNeutralAlarmist
Factuality
0.80 / 1.00
Factual
LowHigh
Sources cited
2
Limited
FewMany
§ 03

Key claims

5 extracted
01

Companies that plan to increase their domestic manufacturing will see a 20% tariff that will increase to 100% in four years.

factualnull
Confidence
1.00
02

The executive order risks creating an “unfair two-tiered system of exemptions” benefiting only big companies.

quoteMidsized Biotech Alliance of America (MBAA)
Confidence
1.00
03

Generic drugs, which make up more than 90% of medicines sold in the US, will be exempted from tariffs for at least one year.

statisticnull
Confidence
1.00
04

Trump threatens 100% tariffs on US drug makers that don’t strike deals to lower prices.

factualnull
Confidence
1.00
05

US patients by far pay the most for prescription medicines, often nearly triple what patients pay in other developed nations.

factualnull
Confidence
0.90
§ 04

Full report

2 min read · 375 words
Donald Trump is threatening 100% tariffs on pharmaceutical companies that have not struck deals to lower US drug prices.The new tariff will only apply to branded drugs and their active ingredients. Generic drugs, which make up more than 90% of medicines sold in the US, will be exempted from tariffs for at least one year. Orphan, veterinary and other specialty drugs are exempt if they are from trade deal countries or meet urgent public health needs.Drugmakers who enter pricing agreements with the White House and onshore drug production will be exempted from the tariffs. Companies that plan to increase their domestic manufacturing will see a 20% tariff that will increase to 100% in four years.The US has already agreed to exemptions for 17 drugmakers, four of which are still being negotiated. Big drugmakers that have signed deals, which exempt them from tariffs for three years, include Pfizer and Eli Lilly, among others.Large companies have 120 days before the rate goes into effect and can negotiate deals with the White House to skirt the tariff or reduce the levy. Smaller companies will have 180 days to negotiate deals.The executive order risks creating an “unfair two-tiered system of exemptions” benefiting only big companies that have already made most-favored-nation deals with Trump, said the Midsized Biotech Alliance of America (MBAA), an industry group.Mid-sized drugmakers “lack diversified portfolios to absorb these sudden cost increases”, Alanna Temme, MBAA’s president, said in a statement.Trump has been pressuring drugmakers through his most-favored-nation drug pricing policy to lower prices to what people pay in other high-income countries. US patients by far pay the most for prescription medicines, often nearly triple what patients pay in other developed nations.The announcement also comes as the White House faces pressure from consumers to lower prices amid other tariff-related price increases, as well as high gas prices triggered by the US-Israel war with Iran.In January, Trump laid out a smorgasbord of economic policies meant to address the rising cost of living, which he has pinned on the Biden administration. Trump has proposed banning large institutional investors from buying single-family homes and capped credit card interest rates at 10%. When teasing policies affecting drug prices, Trump said at the time that “on that alone, we should win the midterms”.
§ 05

Entities

10 identified
§ 06

Keywords & salience

9 terms
drug prices
1.00
tariffs
0.90
pharmaceutical companies
0.80
drugmakers
0.70
trade deals
0.60
prescription medicines
0.50
domestic manufacturing
0.50
most-favored-nation
0.40
generic drugs
0.40
§ 07

Topic connections

Interactive graph
Network visualization showing 51 related topics
View Full Graph
Person Organization Location Event|Click node to navigate|Edge numbers = shared articles